苯甲酸,4-[2-(3,4-二氢-4,4-二甲基-2H-1-苯并吡喃-6-基)-1,3-二硫烷-2-基]- | 156910-58-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 苯甲酸,4-[2-(3,4-二氢-4,4-二甲基-2H-1-苯并吡喃-6-基)-1,3-二硫烷-2-基]-
• 英文名称: [2-(4,4-Dimethyl-3,4-dihydro-2H-1-benzopyran-6-yl)-2-(4-carboxyphenyl)]-1,3-dithiane
• 英文别名: 4-[2-(4,4-Dimethyl-2,3-dihydrochromen-6-yl)-1,3-dithian-2-yl]benzoic acid
• CAS: 156910-58-6
• 化学式: C₂₂H₂₄O₃S₂
• 分子量: 400.563
• InChiKey: DSPWBZDJARQFGY-UHFFFAOYSA-N

物化性质

• 沸点：
  554.0±50.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  97.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• REGULATION OF MUTANT TERT BY BRAF V600E/MAP KINASE PATHWAY THROUGH FOS/GABP IN HUMAN CANCER
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20200323805A1

  公开（公告）日：2020-10-15

  The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for the treatment of cancer characterized by TERT and BRAF mutations. In a specific embodiment, a method for treating a mutant telomerase reverse trancriptase (TERT) enzyme-associated cancer in a subject comprises the step of administering to the subject an anti-cancer agent that inhibits one or more of FOS, GABPB, the formation of the GABPA-GABPB complex or the binding of the GABPA-GABPB complex to a mutant TERT promoter.
• US5837725A
  申请人：——

  公开号：US5837725A

  公开（公告）日：1998-11-17
• [EN] NOVEL COMPOUNDS USEFUL IN MODULATING GENE EXPRESSION OF RETINOID RESPONSIVE GENES AND/OR HAVING ANTI-AP-1 ACTIVITY<br/>[FR] NOUVEAUX COMPOSES UTILES POUR MODULER L'EXPRESSION DE GENES SENSIBLES AUX RETINOIDES ET/OU PRESENTANT UNE ACTIVITE ANTI AP-1
  申请人：SRI INTERNATIONAL

  公开号：WO1995033745A2

  公开（公告）日：1995-12-14

  (EN) Novel compounds are provided which are useful for the regulation of gene expression by retinoids; these compounds are represented by structural formula (I), wherein the substituents R1 through R5 are as defined herein. Additional compounds are provided which are useful for selectively inhibiting AP-1 or an AP-1 component; one group of such compounds is exemplified by structural formula (II), wherein the substituents R1, R2, R20, R21, R22 and R23 are defined herein. Pharmaceutical compositions are provided as well, as are methods of using the compounds in a variety of contexts.(FR) L'invention concerne de nouveaux composés utiles pour réguler l'expression de gènes par les rétinoïdes; ces composés sont structurés selon la formule (I) dans laquelle les substituants R1 à R5 ont la notation mentionnée dans la description. L'invention concerne également des composés utiles pour inhiber de façon sélective l'AP-1 ou un constituant de l'AP-1; un groupe de ces composés est structuré selon la formule (II) dans laquelle les substituants R1, R2, R20, R21, R22 et R23 ont la notation mentionnée dans la description. L'invention concerne enfin des compositions pharmaceutiques ainsi que des procédés d'utilisation de ces composés dans différents contextes.